Preventive Vaccines Market By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, and Conjugate Vaccines, DNA Vaccines, mRNA Vaccines), By Disease Target (Infectious Diseases, Cancer, Autoimmune Diseases), By Distribution Channel (Retail Pharmacies, Hospitals and Clinics, Online Sales), By End-User (Hospitals, Clinics, Public Health Programs), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Preventive Vaccines Market was valued at USD 52.2 billion in 2024-e and will surpass USD 78.4 billion by 2030; growing at a CAGR of 7.0% during 2025 - 2030.

The preventive vaccines market has experienced significant growth, driven by increasing awareness about the importance of vaccination in preventing infectious diseases, cancer, and autoimmune disorders. Vaccination plays a pivotal role in reducing the incidence of infectious diseases, which have historically caused significant morbidity and mortality worldwide. In recent years, advances in vaccine technology, including mRNA and DNA vaccines, have further propelled the market, offering more effective and adaptable solutions for various diseases. As governments, healthcare providers, and the public recognize the importance of preventive healthcare, the demand for vaccines continues to rise.

Additionally, the growing focus on cancer vaccines, especially for cancer prevention and therapeutic purposes, has expanded the scope of preventive vaccines beyond traditional infectious diseases. The integration of innovative technologies such as mRNA and DNA vaccines is revolutionizing the market, enabling faster development and more targeted treatments. With public health initiatives around the globe promoting vaccination and the continued development of new vaccine candidates, the preventive vaccines market is poised for substantial growth in the coming years.

Live Attenuated Vaccines Segment is Largest Owing to Established Effectiveness and Long-Term Protection

The live attenuated vaccines segment is the largest within the preventive vaccines market, owing to the proven effectiveness and long-term protection they offer. Live attenuated vaccines contain weakened forms of the pathogen that cause the disease, which stimulate the immune system to produce a response without causing the actual disease. These vaccines are known for providing long-lasting immunity after a single dose, making them a preferred choice for a variety of infectious diseases, including measles, mumps, rubella, and yellow fever. Due to their proven track record of safety and efficacy, live attenuated vaccines continue to dominate the market, particularly in the prevention of infectious diseases.

Furthermore, live attenuated vaccines are often considered cost-effective due to their ability to provide long-term immunity without requiring multiple booster doses. This has contributed to their widespread use in public health programs worldwide, particularly in low- and middle-income countries, where access to healthcare resources may be limited. The global success of live attenuated vaccines, especially in the fight against infectious diseases, ensures that this segment will remain dominant in the preventive vaccines market for the foreseeable future.

mRNA Vaccines Segment is Fastest Growing Owing to Innovation and COVID-19 Impact

The mRNA vaccines segment is the fastest growing in the preventive vaccines market, largely due to the groundbreaking success of COVID-19 vaccines and the broader application potential of mRNA technology. mRNA vaccines work by instructing cells to produce a protein similar to that of the virus, which then triggers an immune response. This technology has shown remarkable potential in rapidly developing vaccines, as seen with the COVID-19 vaccines, which were developed in record time. The success of these vaccines has spurred interest in mRNA technology for other infectious diseases, cancer, and autoimmune disorders.

The rapid adoption of mRNA vaccines during the COVID-19 pandemic has accelerated investment in mRNA technology, with companies exploring its use for a wide range of diseases beyond COVID-19, such as influenza, HIV, and even certain types of cancer. The flexibility, speed of development, and potential for personalized vaccines are fueling the growth of the mRNA vaccine segment, making it one of the most promising areas in the vaccine industry. As further research is conducted and more vaccines are developed using mRNA technology, this segment is expected to continue its rapid growth and expand the overall preventive vaccines market.

Hospitals Segment is Largest End-User Owing to High Demand for Preventive Healthcare

The hospitals segment is the largest end-user in the preventive vaccines market, driven by the high demand for vaccination as part of routine healthcare and disease prevention. Hospitals are a critical part of the healthcare system, offering comprehensive vaccination services to both inpatients and outpatients. Vaccination programs in hospitals are essential in ensuring that individuals, particularly those in high-risk groups such as infants, elderly individuals, and immunocompromised patients, receive timely vaccinations to prevent various infectious diseases.

Hospitals also play a central role in the administration of preventive vaccines during pandemics, such as the recent COVID-19 pandemic, where hospitals were at the forefront of vaccine distribution. Furthermore, hospitals are key in providing vaccines for emerging diseases, and the ability to manage large-scale vaccination efforts makes them a dominant end-user in the market. The increasing focus on preventive healthcare, coupled with the growing availability of vaccines for various conditions, ensures that hospitals will remain a leading end-user in the preventive vaccines market.

Online Sales Segment is Fastest Growing Distribution Channel Owing to Convenience and Accessibility

The online sales segment is the fastest growing distribution channel in the preventive vaccines market, driven by the increasing demand for convenience and accessibility in healthcare. The rise of e-commerce and online pharmacies has made it easier for consumers to access vaccines, especially in regions where physical healthcare infrastructure may be limited or overcrowded. Online platforms allow for easy ordering and delivery of vaccines, providing a convenient option for individuals who may not have easy access to traditional healthcare settings such as hospitals or clinics.

The COVID-19 pandemic further accelerated the shift toward online sales, as individuals sought to avoid crowded places while still receiving necessary healthcare services. With more consumers becoming comfortable with purchasing healthcare products online, the online sales channel for vaccines is expected to continue growing. As vaccine accessibility becomes increasingly important in global health initiatives, online sales will play a critical role in ensuring widespread distribution, particularly in rural or underserved areas.

Infectious Diseases Target Segment is Largest Owing to Ongoing Need for Disease Prevention

The infectious diseases target segment is the largest within the preventive vaccines market, driven by the ongoing need for disease prevention and control of infectious outbreaks. Vaccines targeting infectious diseases, such as influenza, polio, and tuberculosis, have been widely successful in reducing the incidence and spread of these diseases, saving millions of lives each year. The global push to eliminate infectious diseases, particularly in developing countries, continues to drive the demand for preventive vaccines aimed at protecting individuals from a range of infectious pathogens.

Infectious diseases remain a significant global health threat, and vaccination is one of the most cost-effective and effective ways to control and prevent their spread. The continued focus on immunization programs, particularly in regions with high disease burdens, ensures that vaccines targeting infectious diseases will remain in high demand. With the development of new vaccines for emerging infectious diseases and the ongoing effort to increase vaccine coverage worldwide, this segment will continue to be the cornerstone of the preventive vaccines market.

North America is Largest Region Owing to Advanced Healthcare Systems and High Vaccination Rates

North America is the largest region in the preventive vaccines market, owing to its advanced healthcare systems, high vaccination rates, and strong public health infrastructure. The United States, in particular, has a well-established vaccination program that includes a wide range of vaccines for both infectious diseases and cancer prevention. Public health programs, such as those led by the Centers for Disease Control and Prevention (CDC), play a significant role in promoting vaccination and ensuring high vaccine coverage across the population.

The high demand for preventive vaccines in North America is also supported by a robust healthcare system, where vaccines are readily available in hospitals, clinics, and pharmacies. Additionally, the growing awareness of preventive healthcare and the increasing emphasis on immunization against emerging diseases contribute to the region's dominance in the market. North America is expected to maintain its leadership position in the preventive vaccines market, supported by continued advancements in vaccine technology and public health initiatives.

Competitive Landscape

The competitive landscape of the preventive vaccines market is highly dynamic, with several key players driving innovation and growth. Major pharmaceutical companies such as Pfizer, Merck & Co., GlaxoSmithKline, and Johnson & Johnson are at the forefront of vaccine development, focusing on both traditional vaccine types and newer technologies like mRNA and DNA vaccines. These companies have extensive R&D capabilities and robust distribution networks that enable them to bring new vaccines to market quickly, as seen during the COVID-19 pandemic.

In addition to these large players, smaller biotech companies are emerging with novel vaccine candidates aimed at addressing unmet medical needs, such as cancer vaccines and vaccines for rare infectious diseases. The competitive landscape is characterized by ongoing collaborations between pharmaceutical companies, research institutions, and public health organizations, aimed at accelerating vaccine development and ensuring global access. As innovation continues and new vaccines are introduced, competition will intensify, with a strong focus on improving vaccine efficacy, safety, and accessibility.

List of Leading Companies:

• GlaxoSmithKline
• Merck & Co.
• Pfizer Inc.
• Sanofi Pasteur
• Johnson & Johnson
• AstraZeneca
• Novavax
• Bharat Biotech
• Moderna
• BioNTech
• Serum Institute of India
• Sanofi
• CSL Limited
• Covaxx
• Cadila Healthcare

Recent Developments:

• In January 2025, GlaxoSmithKline announced the launch of a new mRNA vaccine for respiratory infections, set to improve immunity in at-risk populations.
• In December 2024, Merck & Co. received regulatory approval for its new recombinant vaccine against malaria, marking a significant milestone in global vaccination efforts.
• In November 2024, Moderna expanded its COVID-19 vaccine portfolio by introducing an updated version targeting newer variants of the virus.
• In October 2024, BioNTech announced the successful completion of Phase 3 trials for its new cancer vaccine designed to target tumor-specific antigens.
• In September 2024, the Serum Institute of India partnered with global health organizations to supply its new meningitis vaccine to low-income countries at reduced prices.

Report Scope: